Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation
- 1 April 2005
- journal article
- Published by Elsevier in Experimental Cell Research
- Vol. 304 (2) , 604-619
- https://doi.org/10.1016/j.yexcr.2004.12.008
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Forschungsgemeinschaft (Az BR 1873/3-1)
This publication has 41 references indexed in Scilit:
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Exposure to continuous bromodeoxyuridine (BrdU) differentially affects cell cycle progression of human breast and bladder cancer cell linesCell Proliferation, 2004
- Antibodies as molecular target-based therapy: trastuzumabInternational Journal of Clinical Oncology, 2003
- Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growthAnnals of Oncology, 2002
- Evaluating HER2 amplification and overexpression in breast cancerThe Journal of Pathology, 2001
- The EGFR family and its ligands in human cancerEuropean Journal Of Cancer, 2001
- NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancerThe EMBO Journal, 2000
- Augmentation of a humanized Anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225Oncogene, 1999
- EGF induces cell cycle arrest of A431 human epidermoid carcinoma cellsJournal of Cellular Physiology, 1986
- MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGFBiochemical and Biophysical Research Communications, 1985